Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 04:57:06 13/04/2026 pm IST			5-day change	1st Jan Change
1,781.00 ^DKK	-0.50%		+1.80%	-12.04%

10/04	Nordic Equities in North America - Ericsson slips 0.5 percent	FW
09/04	Nordic Equities in North America - Autoliv slips 0.7 percent	FW

Genmab: Darzalex Sales Surpass $3.5 Billion in Q2

Published on 07/16/2025 at 04:03 pm IST

Finwire - Translated by Marketscreener - See original

GENMAB A/S

-0.50%

JOHNSON & JOHNSON

-1.18%

Danish pharmaceutical company Genmab has announced that global sales of the blood cancer drug Darzalex, marketed by Johnson & Johnson, reached $3.539 billion in the second quarter of 2025. The figures were disclosed in a press release.

The sales breakdown shows $2.017 billion generated in the United States and $1.521 billion from the rest of the world.

Genmab receives royalties from the global sales of Darzalex through Janssen Biotech, a subsidiary of the US-based Johnson & Johnson. J&J released its interim report for the second quarter on Wednesday.

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Approximate price	Change	5d. change	Capi.
	GENMAB A/S	1,781.00DKK	-0.50%	+1.80%	1.73TCr
	JOHNSON & JOHNSON	238.46USD	-1.18%	-1.88%	57TCr

Latest news about Genmab A/S

10/04	Nordic Equities in North America - Ericsson slips 0.5 percent	FW
09/04	Nordic Equities in North America - Autoliv slips 0.7 percent	FW
07/04	Nordic Stocks in North America - Astra Zeneca rose 2.1 percent	FW
02/04	Nordic Stocks in North America - AstraZeneca Gains 1.8 Percent	FW
01/04	Nordic Equities in North America - Autoliv Gains 0.7 Percent	FW
31/03	Nordic Equities in North America - Ericsson slides 1.6 percent	FW
30/03	Genmab says Orbis controls 4.99% of Genmab A/S voting rights as of March 27	RE
27/03	Nordic Equities in North America - Ericsson slides 1.5 percent	FW
24/03	Nordic Equities in North America - Ericsson Gains 0.9 Percent	FW
23/03	H. Lundbeck Price Target Down as AlphaValue/Baader Europe Expects Patent Expirations to Weigh on Growth	MT
23/03	Nordic Stocks in North America - Autoliv rose 1.1 percent	FW
19/03	Nordic stocks in North America - Ericsson fell 1.4 percent	FW
19/03	Genmab A/S Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 08:40 AM
18/03	Nordic Stocks in North America - Ericsson Drops 1.2 Percent	FW
16/03	Genmab Wraps Up Share Repurchase Program	MT

Chart Genmab A/S

Duration

Period

GMAB: Dynamic Chart

Company Profile

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).

Employees

2,973

Sector

Biotechnology & Medical Research

Calendar

07/05 - Earnings release - Q1 2026

More about the company